anti glp 1 drugs GLP-1 Drugs: For Multiple Chronic Conditions The anti-inflammatory feature of glucagon-like

Their median left ventricular ejection fraction (LVEF) was 25%, 82% of the patients had ischaemic heart disease, and 59% had type 2 diabetes

For individuals with underlying health conditions such as type 2 diabetes mellitus or obesity, inadequate dosing could increase the risk of long-term complications such as uncontrolled diabetes, kidney diseases, and cardiovascular diseases associated with type 2 diabetes and obesity

A conservative estimate suggests that a 50-pound weight regain costs $5,000 to $15,000 in direct healthcare costs over the following five years through increased medications, more frequent provider visits, and management of weight-related complications

Q: For people who have heard of GLP-1s but dont know much about them, how do they work

If the latter is the case, subscribe by pressing this button: Now, lets get to this weeks topics

At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)